secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2026-08-06T12:49:15+00:00
Accession:  0001628280-26-053940
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Q2 net loss $10.6M; VTP-1000 trial enrollment complete; merger with Clywedog on track
--------------------------------------------------------------------------------

- Net loss of $10.6M ($0.26 per share) vs $5.5M in Q1 2026; cash $59.6M as of June 30.
- Completed enrollment in MAD portion of Phase 1 AVALON trial for VTP-1000 in celiac disease; topline data expected Q4 2026.
- Proposed merger with Clywedog expected to close H2 2026; combined company to trade as CLYD.
- Received Nasdaq extension to Dec 28, 2026 to regain bid price compliance; ADS transferred to Nasdaq Capital Market.
- R&D expenses $3.9M (up from $3.6M Q1); G&A expenses $7.1M (up from $2.5M) due to FX losses and professional fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/0001628280-26-053940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/brns-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer